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Background: Artemis has a defined role in V(D)J recombination and has been implicated in the repair of radiation
induced double-strand breaks. However the exact function(s) of Artemis in DNA repair and its preferred substrate(s)
in vivo remain undefined. Our previous work suggests that Artemis is important for the repair of complex DNA
damage like that inflicted by high Linear Energy Transfer (LET) radiation. To establish the contribution of Artemis in
repairing DNA damage caused by various radiation qualities, we evaluated the effect of over-expressing Artemis on
cell survival, DNA repair, and cell cycle arrest after exposure to high and low LET radiation.
Results: Our data reveal that Artemis over-expression confers marked radioprotection against both types of radiation,
although the radioprotective effect was greater following high LET radiation. Inhibitor studies reveal that the
radioprotection imparted by Artemis is primarily dependent on DNA-PK activity, and to a lesser extent on ATM kinase
activity. Together, these data suggest a DNA-PK dependent role for Artemis in the repair of complex DNA damage.
Conclusions: These findings indicate that Artemis levels significantly influence radiation toxicity in human cells and
suggest that Artemis inhibition could be a practical target for adjuvant cancer therapies.
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Radiation therapy is one of the most broadly prescribed
treatments for malignancy. However, the reasons for the
wide inter-individual variability in response to radiation
therapy are not apparent. Identifying factors that predict
resistance to therapy is an area of intense research that
holds promise to facilitate personalized treatments and
improve outcomes. Here we have identified elevated Ar-
temis levels as being a powerful determinant of radiation
resistance in human cells.
Defects in the Artemis gene were found to be causal in
radiosensitive severe combined immunodeficiency disor-
ders in a subset of Japanese, European, and Native Ameri-
can SCID patients [1,2]. Individuals lacking functional
Artemis are extremely sensitive to radiation and cannot
generate mature B or T cells due to incomplete V(D)J re-
combination which results in immunodeficiency [1]. Arte-
mis has been established as an essential hairpin-cleavage* Correspondence: jmpluth@lbl.gov
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reproduction in any medium, provided the orenzyme in V(D)J recombination, however its exact role in
radioresistance has been more difficult to define. Artemis is
thought to function in non-homologous end joining
(NHEJ), the primary repair pathway for double-strand
breaks (DSBs) in G1 phase of the cell cycle. Artemis has
been implicated as playing a role in this pathway because of
the radiosensitivity associated with Artemis defects and the
functional and physical interactions between Artemis and
the DNA-dependent protein kinase (DNA-PK). DNA-PK
plays a central role in NHEJ repair, phosphorylating itself
and other proteins during the repair process and acting as a
scaffold for repair protein assembly on DNA ends [3]. In
the presence of DNA-PK, Artemis acquires a DNA endo-
nuclease activity which is important for its role in hairpin
processing in V(D)J recombination and perhaps key in pro-
cessing specific radiation-induced substrates in NHEJ [4-7].
Studies have shown that DNA-PKcs recruits Artemis to
DSBs within the chromatin [8,9], aligns the ends of the
DSB to enable Artemis-mediated processing [4], and that
together they can cleave blocked DNA termini [10,11].
A model has been proposed based on accumulated
data that Artemis phosphorylation is not required for itsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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autophosphorylation is, and that the latter modification
allows conformational changes in the DNA that are ne-
cessary for Artemis’ intra-stand incision capability [4].
ATM, DNA-PKcs and ATR (ATM related) have been
shown to phosphorylate Artemis in vitro, evidence sug-
gests ATM is the primary in vivo kinase phosphorylating
Artemis following ionizing radiation [12-17], however
other studies reveal Artemis activity is entirely
dependent on its interaction with DNA-PK [9]. Phos-
phorylation of Artemis by DNA-PKcs or ATM is not
required for the endonuclease activity of Artemis, and
has been shown to be uncoupled from its repair function
[4], although it does influence cell cycle progression
[12]. Studies suggest that phosphorylation of Artemis by
ATM is a negative regulator of G2/M checkpoint, and
that upon repair Artemis is de-phosphorylated [8,12,16].
Despite the role of Artemis phosphorylation on cell cycle
progression, there does not appear to be a clear indica-
tion that phosphorylation is key to its repair function.
An increased sensitivity to agents that induce more
complex damage as compared to simple DSB inducing
agents suggested an important role for Artemis in the re-
pair of complex double strand breaks [10,13]. Previously
we had shown Artemis defective cells exhibit elevated
radiosensitivity, long-term unresolved damage demon-
strated by persistent G1 and G2/M arrest, and a subtle
DSB repair defect, exhibiting ~2 fold more γH2AX foci as
compared to controls [16]. These results are consistent
with earlier findings showing that γH2AX levels can re-
main elevated up to 14 days following alpha particle radi-
ation exposure in Artemis defective-cells [13]. Artemis
function in cellular response to radiation damage is evi-
dent in the hypersensitivity to radiation and persistent cell
cycle arrest following radiation damage in cells lacking Ar-
temis [1,16]. To gain insight into the functions of Artemis
in cell survival after radiation exposure, we exposed
human cells over-expressing Artemis to different qualities
of radiation. Our data reveal that elevated Artemis levels
provide a distinct survival advantage following exposure
to ionizing radiation (IR), and that this effect is more pro-
nounced following high LET exposure as compared to
low LET, consistent with an important role for Artemis in
resolving complex DNA damage. We find that DNA-PK
kinase activity influences the survival advantage imparted
by Artemis over-expression to a greater degree that ATM
kinase activity and that Artemis phosphorylation is
uncoupled from radioresistance.
Results
Elevated Artemis protein levels confer high and low LET
radioresistance
To examine the influence of Artemis levels on cellular
survival after exposure to high and low LET radiation,we used an extensively characterized human expression
embryonic kidney cell line. The wild type line, T-Rex-
293 (hereafter, HEK293), expresses native levels of Arte-
mis and the derivative cell line carries a stably integrated
doxycycline-inducible Artemis cDNA (hereafter, 293Art)
[16] which can be induced to express high levels of Arte-
mis. The T-Rex-293 cell line was chosen for this work
due to its ease of transfection, however our studies have
shown survival responses after radiation treatments
comparable to primary fibroblasts when measured by a
standard clonal survival assay and the BrdU proliferation
assay (unpublished data). Artemis protein levels were
evaluated twenty-four hours after doxycycline treatment
by Western blots of whole cell extracts. Artemis protein
levels in HEK293 were very low, to non-detectable,
whereas 293Art extracts contained high levels of Arte-
mis protein, visualized as an intense band migrating at
~100 kDa on Western blots (Figure 1A inset). Cells sta-
bly retain our inducible Artemis expression plasmid and
tolerate high levels of induced Artemis expression with
no detectable changes in growth, unlike what has been
reported for constructs constitutively producing high
Artemis levels [18]. Artemis protein levels were similarly
validated for all subsequent experiments.
Using these HEK293 and 293Art cell lines we interro-
gated the role of Artemis in cellular survival after expos-
ure to various radiation qualities. Cellular toxicity has
historically been measured with colony formation assays,
where cells capable of continued proliferation form col-
onies that are then stained and counted. To test the ef-
fect of Artemis over-expression on radiation sensitivity
in human cells we first measured how radiation affected
survival in HEK293 versus 293Art cell lines after X-ray
exposure using the clonogenic survival assay. Clonal sur-
vival data indicate that cells having high levels of Arte-
mis are significantly more resistant to X-rays than the
parental cell line having low levels of Artemis
(Figure 1A). To further investigate this result, the same
cell lines were assayed for X-ray toxicity using a different
assay. This assay uses BrdU incorporation into the gen-
ome during replication to measure cellular proliferation
rather than colony formation. Cells are incubated with
BrdU 24 h after radiation and incubated for an add-
itional 24 h prior to harvesting and staining. Thus, cells
staining positive for BrdU have initiated DNA synthesis
in the 24–48 h after radiation and therefore ‘survived’ ra-
diation treatment. We have used this assay to reprodu-
cibly and reliably measure toxicity and cell cycle arrest
following both radiation and genotoxic drug treatments
in normal and hypersensitive mouse and human lines
[11,19,20]. Like the colony formation assay, the BrdU-
proliferation assay also reveals increased radioresistance
in cells with elevated Artemis protein levels (compare
Figure 1A and B).
Figure 1 Elevated Artemis levels confer a radioprotective effect against High and Low LET radiation. Western blots of lysates from human
HEK293 cells carrying integrated vectors harboring tetracycline-inducible Artemis expression constructs (293Art), or control vector (HEK293),
probed with antibodies recognizing Artemis (top) or tubulin for loading controls (bottom) (1A-inset). Results from a clonogenic survival
experiment using HEK293 (open circles) and 293Art Artemis over expressing cells (solid triangles), stained and colonies scored 14 days after
exposure to varied doses of X-rays (A) compared to a BrdU proliferation experiment set up in parallel and harvested 48 h post exposure (B).
Results from BrdU proliferation experiments following high LET exposures in the form of iron nuclei (C) or titanium ions (D) carried out using the
same dose range as X-ray experiments and processed at the same time points.
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sensitivity to high LET exposures plus and minus Artemis
overexpression to assess whether a survival advantage was
observed with exposure to a radiation quality that pro-
duced greater amounts of complex damage. Two different
types of high LET radiation, 1 GeV/u Titanium (LET
~100 keV/u), and 1 GeV/u Fe nuclei (LET~150 keV/u)
were used to investigate this point. As observed following
X-ray exposure, Artemis over-expression significantly
increased the survival of human cells following exposure
to high LET radiation (Figure 1C & D). As expected, a
markedly higher toxicity was associated with high LET as
compared to low LET exposure (Figure 1, compare B, C
and D), however Artemis over-expression consistently
conferred a significant survival advantage with all radi-
ation qualities. Notably, the degree of radioprotection con-
ferred by Artemis over-expression varied with the
radiation quality. The greatest radioprotection was
observed after exposure to Fe nuclei (~3 fold), a lesser de-
gree was observed following Ti nuclei (2.2 fold) exposure,
and the lowest degree of radioprotection was observedwith low LET X-ray exposure (1.7 fold) (Table 1). These
data indicate that high levels of intracellular Artemis pro-
vide a distinct survival benefit following radiation damage
and that the magnitude of this radioprotective effect is ra-
diation quality dependent.
High levels of Artemis accelerate DNA double-strand
break repair
The variant histone H2AX, has been shown to be rapidly
phosphorylated at Ser139 (γH2AX) upon induction of
DNA DSBs and is a stoichiometric surrogate marker for
this type of damage within cells [21,22]. The increase in
phosphorylation and disappearance of phosphorylation
at this site can be quantified by flow cytometry and
faithfully correlates with the kinetics of DSB repair
[23,24]. To evaluate the effect of Artemis over-
expression on early DNA repair after high and low LET
exposures (Fe nuclei and X-ray), we quantified γH2AX
phosphorylation in G1 cells by flow cytometry at thirty
minutes and two hours after exposure. Individual single-
cell flow cytometry data was analyzed and the
Table 1 Calculation of survival parameters based on proliferation assay using the equation
Survival = Exp( - αDose - βDose2)
A. Survival parameters for 293Art Artemis over-expressing Cells
Radiation Type α, Gy−1 β, Gy−2 D37, Gy Fold
293Art/HEK293c
X-rays – 0.057± 0.002 4.21 ± 0.087 1.7
Titaniuma 0.47 ± 0.02 0.034± 0.008 1.86 ± 0.024 2.2
Ironb 0.22 ± 0.002 0.065± 0.007 2.59 ± 0.074 3.0
B. Survival parameters for 293 Wild type Cells
Radiation Type α, Gy−1 β, Gy−2 D37, Gy
X-rays 0.287± 0.033 0.048± 0.006 2.47 ± 0.09
Titaniuma 0.025± 0.044 – 0.85 ± 0.03
Ironb 1.11 ± 0.29 0.086± 0.075 0.85 + 0.15
a Titanium ion 1,000 MeV/u.
b Iron ion 1,000 MeV/u.
c Fold advantage in survival/proliferation following radiation with Artemis overexpression as compared to wild-type cells.
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ted to visualize the DNA damage of cell populations at
these time points. As expected, γH2AX intensity
increased after ionizing radiation exposure relative to
the untreated controls and the levels of damage were
greater with Fe nuclei exposure as compared to X-ray
(Figure 2, compare A&B to C&D). At thirty minutes
after X-ray exposure, cells over-expressing Artemis show
significantly less residual damage relative to the parental
HEK293 (Figure 2A). Two hours after a 2 Gy X-ray ex-
posure the levels of residual γH2AX are nearly equiva-
lent between the two cell lines (Figure 2B). In contrast,
thirty minutes after exposure to 2 Gy of Fe nuclei,
HEK293 and 293Art show virtually no difference in
γH2AX levels (Figure 2C). However, at two hours post
exposure to Fe nuclei the 293Art cells show markedly
decreased γH2AX levels as compared to the parental cell
line (Figure 2D). These data reveal that Artemis over-
expression diminishes γH2AX levels following both high
and low LET exposures, but that the kinetics are differ-
ent between the radiation qualities. These results are
similar to previous results in wild type fibroblast cells
[23] where high LET radiation results in markedly
slower repair kinetics as compared to low LET exposure.
Furthermore, these data suggest that the rate of DNA re-
pair is accelerated by Artemis overexpression for both
high and low LET radiation damage.
Artemis phosphorylation is delayed following high LET
relative to low LET radiation
Artemis phosphorylation status was evaluated at 2 and
48 h following low and high LET exposures to determine
if phosphorylation was temporally regulated with respect
to radiation quality. We find that Artemis phosphoryl-
ation, which results in a mobility shift of the protein onSDS-PAGE, is delayed following high LET exposure rela-
tive to low LET (Figure 3). More specifically, Artemis
protein mobility is markedly altered at early time points
(2 h) after X-rays while a parallel experiment with high
LET radiation shows no change in Artemis protein mo-
bility at this same timepoint (Figure 3A). However, at
48 h after high LET exposure a mobility shift in Artemis
protein is observed, indicative of phosphorylation (com-
pare Figure 3A and B). These data point towards a delay
in Artemis phosphorylation following high LET as com-
pared to low LET exposure, consistent with our previous
studies showing ATM mediated signaling is delayed fol-
lowing high LET relative to low LET exposures in wild
type fibroblast cells [23].
Cells with high Artemis levels show decreased G2/M
accumulation following radiation exposure
DNA damage initiates cell cycle checkpoints that arrest
cell cycle progression until the damage is repaired. To
assess the effect of Artemis over-expression on progres-
sion through the G2/M checkpoint following radiation,
we evaluated cell cycle distributions 48 h after radiation
exposure using the DNA stain propidium iodide (PI).
Cell cycle distribution was evaluated after exposure to
various doses and qualities of ionizing radiation for the
293Art and HEK293 cells (Figure 4).
High Artemis levels had no discernable effect on cell
cycle distributions in the absence of DNA damage. As
expected, both 293Art and HEK293 cells showed a
marked accumulation of cells at the G2/M boundary fol-
lowing radiation exposure and this accumulation
increased at higher doses, and was greater with high LET
as compared to low LET exposure (Figure 4). In previous
studies with Artemis defective cells we observed persistent
cell cycle arrest and an absence of cycling 48 h post
Figure 2 (See legend on next page.)
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Artemis traverse the G2/M checkpoint more readily and
move into G1 to a greater extent than control wild typeHEK293 (Figure 4). Similar results are also observed at
72 h post radiation exposure suggesting that the prolifera-
tion defect in wild type cells is due to a damage-induced
(See figure on previous page.)
Figure 2 High levels of Artemis increase the rate of γH2AX resolution in irradiated cells. Flow cytometry analysis of the distributions of
cells with various γH2AX levels in HEK293 and 293Art cells following exposure to different qualities of ionizing radiation. Comparison of the
distribution of γH2AX signal in control and irradiated cell populations at various times post exposure (left panels), including an enlarged graph of
the irradiated samples (right panels) comparing control HEK293 (dashed lines) and 293Art (shaded). Measurements were taken 30 min after 2 Gy
X-rays (A), 2 h after 2 Gy X-rays (B), 30 min after 2 Gy iron nuclei (C), and 2 h after 2 Gy iron nuclei exposure (D).
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radiation (not shown). Importantly, Artemis over-
expression does not eliminate or bypass the G2/M cell
cycle checkpoint, but rather cells with elevated Artemis
levels have an attenuated biological response to irradiation
with cell cycle kinetics similar to the parental line albeit at
a lower dose (i.e. cell cycle profile of HEK293 at 2 Gy is
comparable to 293Art at 3 Gy, Figure 4). This effect was
observed at different doses and with different radiation
qualities (Fe and Ti), rendering the cell cycle distribution
of 293Art cells at higher doses nearly identical to that of
the parental HEK293 at lower doses (Figure 5, note pat-
terns highlighted by dotted lines).
Artemis over-expression consistently resulted in a larger
percentage of cells cycling into G1 with fewer cells
remaining arrested at G2/M after exposure, a phenomenon
most consistent with an increased DNA repair capacity or
repair rate.
ATM and DNA-PK regulate the radioresistance conferred
by Artemis
Both DNA-PK and ATM are reported to modify Artemis
and to be important mammalian DNA damage signaling
molecules. We next evaluated the functional significance of
these kinase activities on the radioprotective effect impartedA
B
Figure 3 Artemis phosphorylation is delayed following high LET dam
shifts of the protein indicate phosphorylation has occurred. Blots are show
respectively) and 48 h post X-ray or iron nuclei exposure (B, left and right p
Artemis (lower arrow) and hyper-phosphorylated Artemis (upper arrow).by Artemis over-expression. We carried out cell prolifera-
tion assays to quantify the survival advantage of Artemis
over-expression under conditions where ATM or DNA-PK
were catalytically inactivated with inhibitory drugs at a 10
μM concentration, previously shown to totally block radi-
ation induced phosphorylation of down stream targets
[25,26]. As expected, the parental HEK293 cells were sig-
nificantly more sensitive to X-ray treatments when either
ATM or DNA-PK was inactivated with specific kinase inhi-
bitors (Ku55933, or Nu7026 respectively). Under these ex-
perimental conditions, sensitivity to radiation was greater
when DNA-PK was inhibited relative to inhibition of ATM
(Figure 6A). The survival of 293Art cells was likewise influ-
enced by the inhibition of ATM and DNA-PK (Figure 6B),
however the effect of ATM kinase inhibition was signifi-
cantly less pronounced when Artemis levels were elevated
(compare 6A & B, shaded areas). In contrast, DNA-PK kin-
ase inhibition reduced survival dramatically in Artemis
over-expressing cells, approximately two orders of magni-
tude at the highest dose (Figure 6B), similar to what was
observed in wild type cells with DNA-PK inhibition (com-
pare 6A & B). These data imply that the radioprotective ef-
fect conferred by elevated Artemis is significantly more
dependent on DNA-PK than ATM activity. In addition, these
data suggest that the mechanism of the radioprotectionage. Western blots were probed for total Artemis protein and mobility
n 2 h post X-ray or iron nuclei exposure (A, left and right panel
anel respectively). Arrows indicate location of basally-phosphorylated
Figure 4 Artemis over-expression facilitates repair and passage through the G2/M checkpoint. Flow cytometry of propidium iodine
stained cells reveals cell cycle kinetics following various doses of X-ray, Fe ion, or Ti ion exposure. Cell cycle profiles for wild type HEK293 cells are
shown in white and cells over-expressing Artemis (293Art) are Black. Peaks corresponding to location of G1 and G2 cells are indicated at the base
of the figure, with dose and radiation quality noted on the Y and X axis respectively.
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activity of Artemis and DNA-PK, most likely in enhancing
DNA repair.
The kinase dependency of Artemis phosphorylation
following radiation exposure was also examined. Mul-
tiple kinases could potentially phosphorylate Artemis,Figure 5 Quantitation of cell cycle distribution of WT or
Artemis over-expressing cells following exposure to varied
doses of different radiation qualities. Normal wild-type (HEK293)
or these same cells over-expressing Artemis (293-Art) were exposed
to various doses and qualities of radiation. Following radiation cells
were incubated for 24 hours, then labeled for 24 hours with BrdU,
and fixed at 48 hours post exposure. Flow cytometry was used to
quantify the percentage of cells in G1 or G2.therefore in order to assess DNA-PK and ATM activity
on Artemis on phosphorylation levels Western blots of
293Art cells two hours post X-ray exposure (0 Gy,
0.5 Gy, 2 Gy and 4 Gy) were run to assess the phosphor-
ylation status of Artemis in the presence and absence of
inhibitors. In the absence of ATM inhibitor, Artemis
shows a dose dependent increase in phosphorylation,
visualized as a shift in mobility of the band specific for
Artemis protein (Figure 6C, control). Inhibiting ATM
kinase blocks the induction of Artemis phosphorylation
following radiation as exhibited by a lack of shifted Arte-
mis protein on Western blots (Figure 6C, ATMi). Treat-
ment of cells with the DNA-PKcs inhibitor (CSi) only
partially blocked the mobility shift of Artemis, with cells
showing less phosphorylation and lowered levels of
shifted protein (Figure 6C). The latter result suggests
that this phosphorylation is uncoupled from the survival
advantage imparted by Artemis over-expression, as inhib-
ition of DNA PK kinase severely affected the radioprotec-
tive effect but did not affect Artemis phosphorylation.
Furthermore, these data indicate that the mobility shift
associated with Artemis phosphorylation is primarily
ATM dependent whereas the radioprotective effects of Ar-
temis are predominantly DNA-PK dependent.
Discussion
Previous studies by our group and others have shown
that Artemis deficient cells exhibit elevated radiation
A B
C
Figure 6 Effect of kinase inhibitors on the survival advantage imparted by Artemis over-expression and Artemis phosphorylation
following X-ray exposure. BrdU proliferation assays were performed on both wild type HEK293 (A) and cells over-expressing Artemis (B) with
and without two different kinase inhibitors, a ATM kinase inhibitor (ATMi) and a DNA PKcs inhibitor (CSi). Shaded regions on these graphs are for
visual comparison of the effect ATM inhibition on the ability of wild-type versus Artemis over-expressing cells to proliferate post X-ray exposure.
Artemis phosphorylation is indicated by a shift of the total Artemis protein on a Western gel (arrows indicate basally and hyper-phosphorylated
forms) following various doses of X-ray and was also monitored plus ATM inhibition (C) and DNA PKcs inhibition (D).
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implicating a role for Artemis in the repair of a specific
class of DSBs [6,13,16]. Radiation-induced breaks consist
of a combination of closely spaced single-strand breaks,
DSBs, sugar damage, base damage and breaks with
modified ends. Only specific subsets of these breaks are
thought to be processed by Artemis, with other proteins
apparently unable to substitute for Artemis in this func-
tion [10,11,13]. In G1 cells, the majority of radiation-
induced DSBs are rejoined quickly by NHEJ and this
rapid repair appears not to require Artemis or ATM,
however a small subset of slow repairing damages have
been shown to require ATM and Artemis for repair
[13,27,28]. Interestingly, a recent report outlines a re-
quirement for ATM and Artemis in the repair of a frac-
tion of breaks refractory to repair by homologous
recombination in G2 cells as well [29].
Neither the precise role for Artemis in DSB repair nor
its substrate specificity in vivo has been completely
defined. Some studies have suggested a specific role for
Artemis in the repair of complex DSBs, however it’s
exact role in repairing damage caused by high LET radi-
ation remains unclear [13,30]. The current study focuses
on identifying the contribution of Artemis to the repair
of various radiation qualities. In these studies we showthat Artemis over-expression provides a survival advan-
tage post Iron exposure. Data from a representative ex-
periment with Titanium exposure shows a similar
pattern to Iron, again confirming that Artemis protein is
more protective following high LET exposures and that
the level of protection is dependent on radiation quality.
Western blot analysis (Figure 1A insert) verifies the dra-
matically increased Artemis levels in 293Art cells in
comparison to wild type HEK293 cells and further con-
firms the correlation between the increased radioresis-
tance and increased Artemis expression observed in
these cells. High Z particles like Fe and Ti are not com-
monly used in cancer therapeutic regimens as the LET
of these particles in normal tissue at the entrance and
prior to the target site is very high. Typically, low charge
particles like carbon ions are used in particle therapy in
centers offering high LET therapies (such as the Heidel-
berg Ion Therapy Centre (UKL-HD); the Heavy Ion
Medical Accelerator in Chiba, Japan; the CNAO facility
near Milan in Pavia; and GSI in Darmstadt, Germany).
The suitability of carbon is mainly attributed to its low
LET (13 keV/micron) at the entrance of the tissue and
substantial Bragg peak (several hundred keV/micron) at
the site of the tumor. We have used Ti and Fe ions in
these studies as these ion/energy combinations have a
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Bragg peak and therefore mimic the high LET deposited
at the tumor site during therapy.
Studies of γH2AX levels after damage reveal more
rapid resolution of phosphorylated H2AX in cells over-
expressing Artemis. While elevated Artemis levels
reduced the γH2AX signal in cell populations after both
high and low LET damages, the timing of these differ-
ences is distinctly different. Artemis-mediated reduction
in γH2AX levels (indirectly corresponding to reduced
levels of DSBs) following high LET radiation exposures
is only marginally detectable thirty minutes after expos-
ure, however a clear effect is observed at two hours post
exposure (compare Figure 2C & D). In contrast, low
LET damage shows a dramatic difference in γH2AX
levels between Artemis over-expressing and wild type
HEK293 cells at thirty minutes, whereas at two hours
post exposure the control and Artemis over-expressing
cells are nearly indistinguishable (compare Figure 2A &
B). This likely reflects a slower repair of the more com-
plex damage induced by high LET radiation as com-
pared to less complex low LET radiation damage as has
been previously observed [23,31]. Nonetheless, these
data show that Artemis levels significantly influence
γH2AX resolution and likely the repair kinetics follow-
ing both high and low LET radiation.
Inhibition of DNA-PK reveals that the radio-protective
effect of Artemis over-expression was principally reliant
on DNA-PK activity and to a lesser degree on ATM ac-
tivity. In contrast, we find that Artemis phosphorylation,
indicated by a mobility shift of Artemis protein, was pri-
marily dependent on the activity of ATM, as has been
reported previously [14,17,32]. Furthermore, in cells
containing high levels of Artemis, cell proliferation fol-
lowing irradiation was more severely diminished by loss
of DNA-PK activity than by ATM inhibition (compare
Figure 6A & B). Taken together, these data suggest that
Artemis phosphorylation as observed by mobility shifts
may not be relevant to Artemis’ function in the repair of
radiation damage, as we had previously suggested [16].
Conclusions
In summary, our data reveal that elevated Artemis levels
in human cells are able to confer a statistically significant
survival advantage following exposure to ionizing radi-
ation. Moreover, this Artemis-mediated radioprotective ef-
fect is more pronounced following high LET exposures as
compared to low LET damage (Figure 1 and Table 1). We
also find that Artemis over-expression accelerates the
resolution of γH2AX, and by inference the rate of double-
strand break repair in vivo (Figure 2). This latter finding is
entirely consistent with our observation that high levels of
Artemis increase the rate at which cells are able to satisfy
the G2/M checkpoint after radiation damage (Figure 4). Inaddition, we find that Artemis-radioprotection is primarily
dependent on DNA-PK activity and not coupled to the
ATM-dependent phosphorylation (Figure 5). Here we find
that elevated Artemis levels alone can significantly alter
DNA repair and cellular survival following radiation expo-
sures. Our data are most consistent with Artemis func-
tioning in the repair of complex DNA breaks as part of
the NHEJ repair pathway and suggest that that Artemis is
probably rate limiting to this process within human cells.
We have observed increased Artemis levels in a subset of
breast tumors, although we did not find this to be the sin-
gular determinant of radiosensitivity (unpublished data).
These findings suggest that Artemis levels in a subset of
tumor cells may be a useful indicator of responsiveness to
radiation therapy. Moreover, Artemis inhibition may pro-
vide a functional adjuvant in radiation therapy in such
cases, a possibility we are currently investigating.
Methods
T-Rex-293 (Invitrogen) human kidney cells employed in
these studies have a rapid doubling time, high efficiency
of transfection and protein expression, accurate transla-
tion and post translational folding and processing to
generate functional proteins and have been extensively
used as an expression tool for recombinant proteins in
the last three decades. These cells expressing the tetra-
cycline repressor were cultured in DMEM supplemented
with 10% tetracycline-free FBS and 5 mg/ml of blastici-
din. T-Rex-293 cells were transfected with pcDNA4/TO/
Myc-HisA (Invitrogen) carrying wild type Artemis
cDNA, incubated for 48 h and then placed under zeocin
selection (250 μg/ml). Clones were isolated, induced for
Artemis expression with 1 μg/ml doxycycline 24 h prior
to radiation exposure, this induction is maintained dur-
ing the course of the experiment and Artemis expression
levels were evaluated by immunoblotting. For both
γH2AX flow cytometry and the BrdU proliferation assay,
T-25 flasks were plated for each dose and cells were
grown to 85 to 95% confluence prior to exposure.
Irradiation conditions
Cells were exposed to doses ranging from 1 to 6 Gy of
320 kV/X-rays, 1,000 MeV/nucleon Fe, or 1,000 MeV/
nucleon Ti ions (LET of 150 keV/μm and 108.5 keV/μm
respectively). X-ray exposures were performed at
Lawrence Berkeley National Laboratory using a PantakW
X-ray generator operating at 320 kV/10 mA with a
0.5 mm copper filtration and using dose rates ranging
from 5 to 80 cGy/min depending on the dose. Fe and Ti
ion exposures were performed at Brookhaven National
Laboratory, NY using dose rates ranging from 10 cGy to
1 Gy/min depending on the dose. Standard radiation
therapy regimens typically follow a fractionated regimen
of 1.5–2 Gy doses to a cumulative dose of 40–60 Gy,
Sridharan et al. Radiation Oncology 2012, 7:96 Page 10 of 12
http://www.ro-journal.com/content/7/1/96depending on nature of the tumor. Radiation doses used
in this study are comparable to single fraction, or simu-
late an accumulated dose from 2–3 fractions.
Kinase inhibitor treatments
Cells were exposed to an ATM kinase inhibitor (Calbio-
chem, EMD Biosciences, Gibbstown, NJ) and/or a DNA-
Dependent Protein Kinase inhibitor (NU7026 SigmaAl-
drich, St. Louis, MO) in a subset of experiments to define
the relative role of these kinases in imparting the survival
advantage in cells over-expressing Artemis (293Art). For
these experiments cells were pre-incubated with these inhibi-
tors using a 1 μM concentration for 1 h prior to irradiation.
Clonogenic survival assay
For colony formation assays, varying number of cells
(1.5 × 102 to 1× 104) were plated in triplicate 60 cm2 plas-
tic dishes and incubated for 12–15 h at 37°C, 5% CO2
prior to irradiation. Cells were irradiated with X-ray in the
dishes and returned to the incubator for 7–8 days. Result-
ing colonies were stained with crystal violet, scored, and
surviving fraction calculated and plotted.
BrdU proliferation assay
Cells were irradiated with high or low LET radiation,
incubated for 24 h then labeled with BrdU for 24 h, and
finally fixed and stained 48 h after exposure using an
anti-BrdU antibody (20 μl antibody per 1 × 106 cells, BD
Biosciences, San Jose, CA) following product directions.
Cell cycle distribution and BrdU incorporation were
determined by data collected with a Beckman-Coulter
EPICS XLMCL flow cytometer using Cellquest Data Ac-
quisition software, and analyzed using Flowjo (Treestar,
Inc. OR) software. Percentage of G1 cells incorporating
BrdU were determined for each dose and cell line, and
values graphed relative to controls.
Calculation of survival parameters following radiation
exposure
D0 gives the mean lethal dose that delivers an average of
one lethal event/target. When D=D0 the surviving frac-
tion is 37%. We calculated the D37 values for each cell
line and radiation quality, and found them to be consist-
ently lower in wild type HEK293 cells as compared to
the Artemis over-expressing cell line, 293Art. Alpha and
beta components were also evaluated for each cell line
following each radiation quality on the basis of the equa-
tion: S ¼ e∧ αD βD2ð Þ , where S is the survival frac-
tion, D is the dose of exposure and α and β are two
numerical constants. The alpha term is said to dominate at
low dose [linear with dose for log (survival)] and to be due
to single ions or electrons. The beta term is more prevalent
at high dose [quadratic with dose for log (survival)] andsaid to arise from two or more tracks or miss-repair that
increases with dose. If alpha is zero, or very small, then cells
are resistant and only beta contributes.
Flow cytometry analysis of γH2AX kinetics
Irradiated and mock-irradiated flasks were fixed at vari-
ous times after exposure. Cells were harvested and fixed
with 100% ice-cold methanol added drop-wise while vor-
texing. After fixation, cells were placed at −20°C until
stained. Cell suspensions were counted prior to staining
and diluted to 1.0 × 106/ml. For staining, an aliquot of
the fixed cells containing 0.5 × 106 was removed and
washed in PBS. Cells were placed in a blocking solution
containing 2% FBS/PBS and incubated for 1 h with a pri-
mary mouse monoclonal γH2AX antibody (1:800 dilu-
tion) from Molecular Probes (Invitrogen, Carlsbad, CA)
on ice. After incubation, cells were pelleted, washed in
PBS, and incubated in a secondary goat anti-mouse anti-
body (1:400 dilution) from Molecular Probes (Invitrogen,
Carlsbad, CA) diluted in blocking solution. After 1 h
additional incubation on ice under foil, cells were pel-
leted and washed for a final time in PBS. Flow cytometry
was used to define cell cycle status by staining cellular
DNA with propidium iodide (10 μg/ml PI, Roche Ap-
plied Science, Indianapolis, IN) in a solution containing
RNase (100 μg/ml, Sigma-Aldrich, St. Louis, MO). Me-
dian values of fluorescent signals corresponding to
γH2AX levels were obtained for each control and irra-
diated sample (X-ray or 1,000 MeV/u Fe ion). Cell data
was collected on a Beckman-Coulter EPICS XLMCL
flow cytometer using Cell quest Data Acquisition soft-
ware, and analyzed using Flowjo (Treestar, Inc. OR) soft-
ware. Individual cell data was exported for analysis and
data is expressed as relative increase in phosphorylation
level over controls for each experiment.
Western blots
Cells were harvested and resuspended in cold high salt
lysis buffer (20 mM Tris, pH 8.0; 600 mM NaCl; 1 mM
EDTA; 0.5% Igepal) containing protease inhibitor cock-
tail from Calbiochem (1 mM PMSF, 1 mM Na3VO4,
and 1 mM NaF), incubated on ice for 30 min with occa-
sional vortexing, and then sonicated. Lysates were spun
at 14,000 rpm for 20 min at 4°C, and protein concentra-
tion determined using the Biorad BCA protein assay.
Loading buffer (187.5 mM Tris, pH 6.8; 6% SDS; 30%
Glycerol, and 10% 1 M DTT) was added to samples,
which were boiled and spun down. Samples were loaded
onto a 7% SDS-PAGE gel and run for 1 h at 150 V (Run-
ning buffer: 25 mM Tris, 192 mM Glycine, 0.1% SDS).
Proteins were transferred to 0.2um PVDF membrane at
4°C, 30 V, over night in Transfer Buffer (20% MeOH,
50 mM Tris, 400 mM Glycine, 0.1% SDS). After the
transfer, blots were rinsed with Tris buffered saline
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BSA-TBST for 1 h prior to antibody addition. Primary
antibodies were incubated at each dilution and time spe-
cified: Tubulin (1:5,000 for 1 h, Sigma-Aldrich, St. Louis,
MO) and total Artemis 1024 anti-sera (1:1,000 for 1 h).
A description of total Artemis anti-sera production was
described previously [16]. Briefly, a ~600 bp fragment of
Artemis was sub-cloned into pET-15b (Novagen) vector
and expressed in E. coli. Artemis protein from these cells
was then purified according to the manufacturers direc-
tions (pET System Manual, Novagen). Purified protein
was used to generate rabbit antiserum (Bethyl Labora-
tories). Secondary antibodies were either anti-mouse-
HRP from GE Healthcare (1:15,000 or 1:10,000; 1 h) or
anti-rabbit-HRP from Cell Signaling (1:5,000 or 1:10,000;
1 h). Blots were washed for 3 × 10 min after the primary
and secondary incubations with TBST. ECL Substrate
was either ECL Supersignal West Pico from Pierce or
ECL Plus from GE Healthcare.
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